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Abstract 
 
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and accounts for over 
90 % of all diabetes cases worldwide. Type 2 diabetes is characterized by insulin resistance 
and relative insulin deficiency, either of which may be present at the time that diabetes 
becomes clinically manifest. Genetic background was perceived to be linked with the 
development of T2DM and its related complications including retinopathy, nephropathy, 
diabetic foot and cardiovascular disease. Several variants in the FTO gene were analyzed and 
found to be associated with T2DM and obesity in different population. Therefore, our study 
was designed to investigate the association of FTO (rs9939609) gene polymorphisms with 
T2DM and its related complications. 
A case-control study was conducted during the period of 2016-2017. A total of 281 diabetic 
patients (181 obese and 15 non-obese) and 118 controls (52 obese and 39 non-obese) were 
recruited. All of them were unrelated and aged ≥40 years. The anthropometric, clinical and 
biochemical data was collected on a structured questionnaire. The single nucleotide 
polymorphism (SNP) in the FTO gene was identified by PCR-RFLP. Comparison of allele 
frequencies and genotype distributions between the diabetic and non-diabetic groups were 
done using the Pearson‟s Chi-square test. R statistics (v2.8.0). software was used to measure 
OR for T2DM adjusted for age, gender and BMI. 
Our results showed a strong association between the minor allele A at rs9939609 of the FTO 
and increase T2DM risk with an allelic odd ratio (OR) of 1.84, (95%CI [1.04-3.05], P=0.034) 
after adjustment by age, gender and BMI. Stratified data by glycemic status and across FTO 
genotype, revealed a marginally association between the FTO A variant and body mass index 
(BMI) in the diabetic group (P=0.057), while no association was found in non-diabetic 
control group (P=0.688). Furthermore, no significant association was observed between FTO 
genotypes and covariates of age, gender, T2DM complications or any tested metabolic trait in 
both diabetic and non-diabetic individuals (P>0.05). 
In conclusion, our results demonstrated FTO rs9939609 variant was associated with T2DM. 
However, further large-scale study is required to elucidate the role of this variant on the 
predisposition of increased BMI in Palestinian population. 
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Chapter One 
 
1. Introduction 
1.1 Diabetes Mellitus 
Diabetes mellitus (DM) is a group of metabolic diseases that characterized by persistently 
elevated blood glucose levels (hyperglycemia) with disturbances in fat, carbohydrate and 
protein metabolism as a result of defects in insulin secretion, insulin action (insulin 
resistance), or both. If diabetes is undiagnosed or poorly controlled, it can lead to a state of 
persistent chronic hyperglycemia. The chronic hyperglycemia of diabetes is associated with a 
different complications and irreversible damage in a wide range of important organs, like the 
kidney glomeruli, eyes, neural tissue, heart and blood vessels (Tibaldi, 2012). 
 
1.2 Classification of Diabetes mellitus 
Recently, the old and confusing terms of non-insulin-dependent (NIDDM) or insulin-
dependent (IDDM) which were suggested by World Health Organization (WHO) in1980 and 
1985, have disappeared and the terms of new classification system identifies four types of 
DM as follow: 
a) Type 1 diabetes mellitus (T1DM) 
This type of diabetes was previously known by different names; juvenile diabetes, insulin 
dependent diabetes or immune-mediated diabetes. It accounts for only 5–10% of all diabetes 
cases, and is thought to be caused by destruction of insulin producing cells of the pancreas, 
primarily to an autoimmune-mediated reaction, resulting in absolute insulin deficiency 
(AAD, 2010). The reason why this occurs is not fully understood. In general, T1DM is 
diagnosed at any age, but most frequently it develops during childhood and adulthood. People 
with T1DM are usually insulin-dependent and require daily injections of insulin to regulate 
their glucose levels and to prevent progression of the disease. 
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b) Type 2 diabetes mellitus (T2DM) 
T2DM is considered the most common form of diabetes and account for 90-95% of all 
diabetes cases worldwide and was previously referred to non–insulin dependent diabetes or 
adult-onset diabetes (González, Johansson, Wallander, & Rodríguez, 2009). T2DM 
characterized by reduced responsiveness of cells to insulin (known as insulin resistance) and 
patients usually have relative insulin deficiency (insulin produced but not enough to prevent 
hyperglycemia). T2DM usually occurs after the age of 35-40 years but may be diagnosed 
earlier, especially in populations with high diabetes prevalence. T2DM frequently goes 
undiagnosed (asymptomatic) for many years and the diagnosis is often appear from 
associated complications or incidentally through an abnormal blood glucose level or urine 
glucose test (Lu et al., 2012). T2DM is often, but not always, associated with metabolic 
abnormalities such as obesity and most patients with this form of diabetes may have an 
increased percentage of body fat distributed predominantly in the abdominal region, which 
itself can cause insulin resistance and lead to elevated blood glucose levels. In contrast to 
T1DM, patients with T2DM do not require exogenous insulin, but may require insulin to 
control glucose levels if this is not achieved by recommended diet alone or with 
hypoglycemic drugs (Thévenod, 2008) . 
 
c) Gestational diabetes mellitus (GDM) 
This type of diabetes has been defined as any degree of glucose intolerance with onset or first 
detection during pregnancy and usually diagnosed in the second or third trimester of 
pregnancy (Cypryk, Szymczak, Czupryniak, Sobczak, & Lewiński, 2008). GDM account for 
about 2% - 10% of pregnant women. The risk of GDM increased in older mothers especially 
over the age of 30 years of age, women with a family history of type 2 diabetes, who are 
overweight, who have had a previous pregnancy with gestational diabetes, who have had 
large babies or obstetric complications and woman who have had polycystic ovarian 
syndrome. Maternal hyperglycemia may lead to complications in the baby, including birth 
trauma, large size at birth, hypoglycemia and infant respiratory syndrome (H. S. C. R. Group, 
2008; Mpondo, Ernest, & Dee, 2015). 
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d) Other specific type (Monogenic diabetes) 
There are specific types of diabetes due to many causes including monogenic diabetes 
syndrome resulting from genetic defects of β-cells function, neonatal diabetes and maturity-
onset diabetes of the young [MODY], diseases of the exocrine pancreas (e.g. cystic fibrosis), 
and diabetes induced by drugs or chemicals (in cases of the treatment of HIV/AIDS or after 
organ transplantation) (Association, 2010). 
 
 
1.3 Risk factors for T2DM 
T2DM is a very complex disease, and its development includes several risk factors that may 
include genetic factors, family history (first-degree relative) and pre and post-natal 
environmental factors. Genetic factors results in certain patterns of DNA sequence whereas 
pre and post-natal environmental factors include a wide range of elements; suboptimal 
intrauterine environment, low birth weight, obesity, physical inactivity, history of gestational 
diabetes, hypertension or dyslipidemia, polycystic ovarian syndrome leading to insulin 
resistance and finally, decline in insulin secretion due to advancing age (Jin & Patti, 2009). 
Figure (1.1) summarize the risk factors and their potential role for T2DM. 
 
 
Figure 1.1: Multiple risk factors for T2DM, including classical genetic risk (family history) as well as a 
prominent contribution from multiple environmental risk factors (adopted from Jin & Patti, 2009). 
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1.4 Epidemiological transition of diabetes mellitus 
DM is now recognized as one of the main public health challenges of the 21
st
 century and it‟s 
considered sixth leading cause of death. People suffering from DM have twice the risk of 
death as comparing with others of the same age without diabetes. The main cause of death in 
diabetic patients is not from diabetes itself but from the complications of the disease (Rich, 
Norris, & Rotter, 2008). WHO estimates that, globally, 422 million adults aged over 18 years 
were living with diabetes in 2014 and this number may be elevated in 2035 to 592 million 
(Organization, 2016).  In every country the whole number of people with T2DM is raising. 
The highest number of people detected with diabetes is 40 and 59 years of age. 
 
Statistical reports show that about 5.1 million deaths due to diabetes were reported in 2013, 
meaning that every six seconds a person dies from diabetes (Guariguata et al., 2014). This 
epidemic relates particularly to T2DM which accounts for the most diagnosed cases of DM. 
Also, the highest prevalence of DM was in high-income countries (7.8 %) resulted from 
changes in the lifestyles and decrease physical activity and increase obesity (Shaw, Sicree, & 
Zimmet, 2010). In the Middle East, the prevalence of T2DM in these countries could reach 
60 million diabetes patients in 2030 (Klautzer, Becker, & Mattke, 2014).  
 
In Palestine, Studies enlightening the epidemiology of diabetes mellitus among Palestinians 
populations are scarce. In 2000, a study on the prevalence of DM in Palestine was conducted 
in Kober village located north east of the city of Ramallah in the center of the West Bank by 
Birzeit University, the prevalence of diabetes was 9.6% and 10.0% in females and males 
respectively (Husseini, 2000). Another two cross-sectional studies was conducted in 
Ramallah governorate showed a higher rate of this disease in an urban community (12.0%) 
than in a rural community (9.8%) at age 30–65 years (Abdul-Rahim et al., 2001; Husseini, 
2000). 
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1.5 Diagnostic criteria of Type 2 diabetes mellitus 
Diagnosis of T2DM is based on fasting plasma glucose (FPG) concentration and/or 2-hour 
plasma glucose (2hPG) concentration during an oral glucose tolerance test (OGTT). T2DM is 
preceded by a pre-diabetic state, which are characterized by mild increasing of fasting or 
postprandial glucose levels. This state may last for years, and about one third of individuals 
with pre-diabetes finally develop T2DM (Unwin, Shaw, Zimmet, & Alberti, 2002). Pre-
diabetes status is defined by an OGTT, which includes impaired glucose tolerance (IGT, 
characterized by an elevated 2hPG), impaired fasting glucose (IFG, characterized by an 
elevated FPG), or both. The diagnostic criteria for IFG and IGT according to the American 
Diabetes Association (ADA)  (Genuth et al., 2003) and World Health Organization (WHO) 
(Organization, 1999) are shown in table (1.1). 
 
 
Table 1.1: Diagnostic criteria of glucose tolerance categories according to the WHO (Organization, 1999) and 
ADA (Genuth et al., 2003) criteria. 
 
 
 
 
Measure 
American Diabetes Association 
 
World Health Organization 
 
Diabetes 
 
pre-diabetes 
 
Diabetes 
Impaired 
Glucose 
Regulation 
Fasting plasma glucose 
(FPG) 
≥126 mg/dl 100–125 mg/dl 
(IFG) 
≥126 mg/dl 110–125 mg/dl 
(IFG) 
2-Hr plasma glucose 
(during an OGTT with 
a loading dose of 75 g) 
 
≥200 mg/dl 
 
140–199 mg/dl 
(IGT) 
 
≥200 mg/dl 
 
140–199 mg/dl 
(IGT) 
Casual (or random) 
plasma glucose (in a 
patient with classic 
hyperglycemic 
symptoms) 
 
 
≥200 mg/dl 
  
 
≥200 mg/dl 
 
Glycated hemoglobin  ≥6.5% 5.7–6.4% ≥6.5%  
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1.6 Pathogenesis of Type 2 diabetes mellitus 
Under normal physiological conditions, plasma glucose levels are maintained within a narrow 
range and well balance to regulate interaction between tissue sensitivity to insulin (especially 
in liver) and insulin secretion, known as glucose homeostasis (Boden, 1996). In T2DM these 
mechanisms break down due to two main pathological defects:  
a) Impaired insulin secretion due to a dysfunction of the pancreatic β-cells leading to a 
relative insulin deficiency (Chiu et al., 2007). 
b) Impaired insulin action due to insulin resistance caused by defects in the signaling 
pathways that process the insulin signal in its target tissues (Wolfs, Hofker, Wijmenga, & 
Van Haeften, 2009). 
 
However, several studies reported that T2DM is developed when the pancreas is unable to 
produce more insulin to compensate for existing insulin resistance. According to this, insulin 
resistance will be present early in the natural history of this disease, whereas marked β-cell 
dysfunction is a rather late event (Martin et al., 1992). In addition, both impaired insulin 
secretion and insulin resistance are influenced by genetic and environmental factors. 
 
1.6.1. Impaired insulin secretion 
Insulin is released from the β-cells of pancreatic islets in response to changes in blood 
glucose level. In brief, the process begins by transferring glucose to β-cells through diffusion 
facilitated by GLUT2 transporter. In the β-cell, glucose is metabolized to generate ATP and 
thus the ATP/ADP ratio increases leading to closure of cell-surface ATP-sensitive K+ 
channels (KATP channel) and these channels are capable of modulating insulin secretion in 
response to fluctuations in plasma glucose levels, and thus are an important regulators of 
glucose homeostasis. Accordingly, depolarization of the cell-membrane occurs and 
subsequently the Ca
2 +
 dependent channels are opened, facilitating extracellular flow of Ca
2+
 
in the β-cell which triggers the exocytosis of insulin as shown in figure (1.2). 
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Figure 1.2: Insulin secretion by the beta-cell of the pancreatic islets (adopted from(Henquin, Ishiyama, 
Nenquin, Ravier, & Jonas, 2002). 
  
      
The Insulin release process from the pancreatic β-cells takes place in two phases in response 
to a rapid increase in blood glucose level. The first phase, which is a short-term period 
(occurs within a few minutes) and characterized by an increase in insulin secretion, is 
followed by a more slowly evolving second phase, which lasts as long as the glucose level is 
elevated. On the other hand, a slow increase in plasma glucose level induces a gradually 
larger secretion without the first phase (Henquin, Ishiyama, Nenquin, Ravier, & Jonas, 2002). 
 
In type 2 diabetic patients, the first phase of insulin secretion is lower than in healthy 
subjects, and is often absent, the second phase also much lower than in non-diabetic subject. 
Moreover, the impairment of both first and second phase insulin release occurs early in the 
natural history of diabetes (Gerich, 2002). 
 
Pancreatic β-cell failure in T2DM can be due to several potential causes: 
 Reversible metabolic abnormalities (glucotoxicity and lipotoxicity).  
 Hormonal changes (inadequate secretion and action). 
 Moderate reduction in total mass of pancreatic islet tissue due to apoptosis, and genetic 
abnormalities. 
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Chronic hyperglycemia has been shown to induce β-cell dysfunction and apoptosis in human 
cells leading to mitochondrial weakness, production of reactive oxygen species and increased 
levels of intracellular calcium, which leads to glucotoxicity (Wajchenberg, 2007). 
 
Elevation of free fatty acid levels (FFA) can also contribute to β-cell dysfunction through 
promote pro-apoptotic effect as result of endoplasmic reticulum stress, or through the 
intracellular accumulation of triglycerides as a response to the activation of the sterol 
regulatory element binding proteins (SREBP), that regulate cellular ATP production and 
leads to lipotoxicity (Joseph et al., 2004). The deleterious effects of FFAs are observed 
predominantly in the presence of high glucose. On the other hand,  there are several 
hormones such as  glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) which are important gut hormones that released after food intake, and have 
been shown to increase β-cell proliferation and decrease β-cell apoptosis (Drucker, 2006). 
 
1.6.2. Insulin signaling pathway 
When blood glucose level rises, insulin released by the pancreatic β-cell and then begin to 
exercise biological functions through interaction with membrane-spanning insulin receptor 
(IR) on muscle cells and/or adipocytes and facilitated dimerization of the receptor. As a result 
of this dimerization the receptor is autophosphorylated at specific residues, leading to binding 
of various scaffold proteins such as insulin receptor substrate (IRS) proteins. IRS proteins are 
activated by phosphorylation of by their association with the p85 regulatory subunit of 
phosphatidylinositol 3-kinase (PI3K). Followed by actions of phopshoinositide-dependent 
protein kinase-1 (PDK1) and protein kinase B (PKB or Akt). AKt binds to domain of PKB, 
and thus promotes glucose uptake by the GLUT4 transporter and glycogen synthesis 
(Changeux & Edelstein, 2005). These mechanism of insulin signaling pathway was described 
in figure (1.3). Other effects of insulin, such as its effect on protein synthesis, glycogen 
synthesis, lipogenesis and suppression of hepatic glycogenesis are also mediated by PKB. 
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Figure 1.3: The mechanism of insulin signaling pathway (adopted from (Changeux & Edelstein, 2005)) 
 
 
Insulin resistance 
Insulin resistance can be defined as the inability of tissues to respond properly to normal 
circulating insulin. To maintain a normal concentration of blood sugar, the pancreas 
compensates by secreting increased amount of insulin. However, high levels of insulin can 
compensate for poor insulin action only for a limited time. After a period of insulin 
resistance, pre-diabetes usually develops, especially in co-existence with impaired of β-cell 
functions. An early onset of insulin resistance in the natural history of diabetes was 
demonstrated by Vaag et al., in 1992 as they found that young healthy offspring of diabetes 
parents usually show insulin resistance and impaired skeletal muscle insulin signaling many 
decades before the onset of T2DM (Vaag, Henriksen, & Beck-Nielsen, 1992). 
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Although the exact mechanism resulting in insulin resistance is not clear, multiple 
abnormalities in the insulin signaling pathway have been identified. According to insulin 
signaling pathway, the most important site is IRS (IRS1 and IRS2), PI3K and PKB. 
Therefore, any mutation in one of these sites lead to enhanced insulin resistance, e.g. a 
mutation in the IRS1 gene in human are associated with insulin resistance (Whitehead, 
Humphreys, Krook, & Jackson, 1998) and reduced activation of the PI3-kinase/Akt signaling 
pathway which  lead to reduction of  glucose transport and utilization in the skeletal muscle 
and adipocytes (Mulder, Ahren, Stridsberg, & Sundler, 1995). Moreover, there are still 
several other causes of insulin resistance which are summarized in table (1.2). 
 
Table 1.2: Some causes of insulin resistance 
Cause No. Cause 
1 Obesity/overweight (especially excess visceral adiposity). 
2 Pregnancy, gestational diabetes. 
3 Excess glucocorticoids (Cushing‟s syndrome or steroid therapy). 
4 Excess growth hormone (acromegaly). 
5 Lipodystrophy (acquired or genetic, associated with lipid accumulation in 
liver). 
6 Mutations of the peroxisome proliferators‟ activator receptor γ (PPAR). 
7 Hemochromatosis (a hereditary disease that causes tissue iron accumulation). 
8 Polycystic ovary disease. 
9 Autoantibodies to the insulin receptor. 
 
 
1.7 Complications of type 2 diabetes mellitus 
Improper management and treatment of T2DM can lead to very high levels of blood glucose 
and a number of serious health problems such as macrovascular and microvascular 
complications. Microvascular complications include retinopathy, neuropathy, nephropathy 
(which may lead to renal failure), blindness and lower limb amputation (diabetic foot). 
Macrovascular complications include cardiovascular disease (CVD) and stroke. 
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1.7.1. Microvascular complications of T2DM 
Microvascular complication is developed through aldose reductase enzyme mechanism. This 
enzyme is considered the first enzyme in the intracellular polyol pathway. This pathway is 
working on converting of glucose to sorbitol (glucose alcohol). In hyperglycemic status, the 
flux of sugar molecules through the polyol pathway will be increasing, which causes sorbitol 
accumulation in cells and promotes osmotic stress (Gabbay, 1975). It has been suggested that 
osmotic stress is the mechanism by which diabetic microvascular complications were 
developed.  
 
a) Diabetic retinopathy (DR) 
DR is considered the most common microvascular complication that can affect the peripheral 
retina, the macula, or both and is a leading cause of visual disability and blindness in people 
with T2DM. The prevalence of DR in patient with T2DM is between 40-50% which can be 
increased with prolonged duration of diabetes (Cheung, Mitchell, & Wong, 2010). The major 
risk factors for rapid progression of DR in patients with T2DM has been found to be related 
to several factors including; increasing age, duration of diabetes, poor control of blood 
glucose hypertension, obesity, alcohol consumption and genetic factors (e.g. Aldose 
reductase gene) (Rivera et al., 2017) . 
The severity of DR ranges from mild non-proliferative and pre-proliferative to more severely 
proliferative DR. Mild non-proliferative DR is characterized by the microaneurysms and hard 
exudates. In pre-proliferative DR, there might be intraretinal hemorrhages, soft exudates, 
venous beading and intra-retinal microvascular abnormalities (Elwali et al., 2017). 
 
b) Diabetic neuropathy 
Diabetic neuropathies are neurological disorders caused by diabetes, so people with T2DM 
can, over time, may develop nerve damage throughout the body. Some of these people have 
no symptoms, while others may have symptoms such as problems with urination, numbness, 
tingling, wasting of the muscle of the feet or hands, indigestion, nausea, or vomiting. 
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The risk of development of diabetic neuropathy is directly proportional to several factors 
(Fowler, 2008) such as: 
 Metabolic factors such as high blood glucose, abnormal blood fat levels, long duration of 
diabetes and possibly low levels of insulin.   
 Neurovascular factors which lead to damage the blood vessels carrying oxygen and nerve 
nutrients. 
 Autoimmune factors (inflammation in nerves). 
 Inherited traits that increase susceptibility to nerve disease.  
 Lifestyle factors such as tobacco or alcohol use.  
 Mechanical injury to nerves such as carpal tunnel syndrome. 
 
c) Diabetic nephropathy (DN) 
DN is characterized by an increased urinary albumin excretion (UAE) in the absence of other 
renal diseases. It is considered the most common cause of end stage renal disease (ESRD) 
(Bakris, 2011).  Clinical evidence associated with DN refers to the presence of abnormal 
level of albumin in the urine (>30 mg/day or 20µg/min; urinary albumin/creatinine ratio 
[ACR] >3.0 mg/mmol), known as microalbuminuria. In T2DM, the prevalence of DN varies 
between 5-20%, 38% developed to microalbuminuria and 29% developed renal impairment 
after 15 years of follow up (Retnakaran, Cull, Thorne, Adler, & Holman, 2006). 
The pathogenesis of DN is similar to other microvascular complications and caused by the 
association of both metabolic alterations (possibly hyperlipidemia and hyperglycemia) and 
haemodynamic alterations (systemic and glomerular hypertension). Hyperglycemia plays role 
in induced oxidative stress and the activation of several metabolic pathway such as advanced 
glycation end-product (AGE), protein kinase C (PKC) and polyol pathway which lead to 
evolution of DN (Cade, 2008; Dronavalli, Duka, & Bakris, 2008). Haemodynamic alterations 
occur as a result of the activation of different vasoactive systems, such as endothelin systems 
and renin–angiotensin–aldosterone (RAAS), which arise in response to the secretion of pro-
fibrotic factors, such as transforming growth factor β1 (TGF-β1), resulting in increased 
systemic and intraglomerular pressure (Dronavalli et al., 2008).  
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The risk of development of microalbuminuria in T2DM was associated with several factors 
such as: 
 Elevated systolic blood pressure. 
 Waist circumference. 
 Previous cardiovascular disease. 
 Smoking history. 
 Elevated plasma triglycerides. 
  Gender especially male. 
 
1.7.2. Macrovascular complications of T2DM 
Cardiovascular diseases (CVD) are the principal cause of mortality (~70%). Patients with 
T2DM are considered to have a 4-fold-greater risk for developing a CVD than people without 
T2DM after controlling for traditional risk factors for CVD, such as, age, smoking, high 
blood pressures, high serum cholesterol and obesity (Bugger & Abel, 2014). These 
cardiovascular risk factors are common in diabetes, but recent studies and data suggest that 
diabetes is an independent risk factor for cardiovascular disease (Forbes & Cooper, 2013). 
Patients with T2DM also exposed to the risk of premature atherosclerosis and development of 
Myocardial Infarction, impaired cardiac function and stroke. Recent data suggest that type 2 
diabetic patient also have a 5-fold-greater risk for a first Myocardial Infarction and a 2-fold-
greater risk for a recurrent Myocardial infarction than people who previously had a 
Myocardial Infarction but do not have diabetes (Forbes & Cooper, 2013; Kalofoutis et al., 
2007).  
 
1.8 Risk Factors for the development of T2DM Complications 
Several factors play multiple roles in duration and control of the disease. They include: 
a) Elevation of blood pressure has a significant effect on CVD in people with T2DM 
compared with non-diabetic individuals. Thus the control of blood pressure (<130/80 
mmHg in adults) will have an effective reduction of cardiovascular morbidity and 
mortality in T2DM patients (Donaghue, Chiarelli, Trotta, Allgrove, & Dahl-Jorgensen, 
2009).  
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b) Familial history of complications worsens the risk for nephropathy (Prasad et al., 2006) 
and retinopathy (Dorchy, Claes, & Verougstraete, 2002). 
c) Higher body mass index (BMI) is a documented risk factor for neuropathy, retinopathy 
(Dorchy et al., 2002), cardiovascular disease and microalbuminuria (Fowler, 2008). 
d) Life style: low physical activity individual with T2DM had a higher mortality rate than 
those with high physical activity (Moy et al., 1993). 
e) Microalbuminuria predicts strictly cardiovascular morbidity and mortality in individuals 
with T2DM (Tagle, Acevedo, & Vidt, 2003). A cohort study conducted by (Valmadrid, 
Klein, Moss, & Klein, 2000) showed that the risk for CVD was doubled in patients with 
microalbuminuria compared to those without. 
f) Dyslipidemia: high levels of triglycerides, low level of HDL-C and high level of LDL-C, 
is a risk factor for macrovascular diabetic complications. Lowering LDL-C with diet or 
lipid-lowering medication has an important effect in reducing the cardiovascular risk of 
patients with T2DM (Howard et al., 2000). 
 
1.9. Literature review 
1.9.1. Genetics of type 2 diabetes mellitus 
It is generally agreed that T2DM has a strong genetic component. There are several evidences 
supporting this view. First, the prevalence of T2DM varies across different ethnic groups and 
it is modified by genetic admixture (Florez, Hirschhorn, & Altshuler, 2003). Secondly, 
T2DM often exhibits familial aggregation (Rotimi, Cooper, Cao, Sundarum, & McGee, 
1994). The estimated risk of developing T2DM is 40% for individuals who have one parent 
with T2D and almost 70% if both parents are affected (Kobberling, 1982). Furthermore, the 
relative risk for first degree relatives has approximately 3.5-fold increased risk of developing 
the disease for those with single diabetic parent, and ~6-fold if both parents are affected 
compared with offspring without parental diabetes (Meigs, Cupples, & Wilson, 2000). Third, 
twin studies showed  a high concordance of type 2 diabetes in monozygotic twins 
(concordance rates of over 90%), whereas in dizygotic twins the concordance is about 50% 
lower than in monozygotic twins (concordance rates of 9-16%) (Wolfs et al., 2009). Finally, 
there is a strong heritability of intermediate phenotypes, since both insulin secretion and 
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insulin sensitivity have an important genetic component  (P. Poulsen, Kyvik, Vaag, & Beck-
Nielsen, 1999). 
 
Genetic contribution to T2DM arises from genetic differences in many genes, each conferring 
a small increase in the risk. These genes variations do not cause diabetes but increase their 
risk through interaction with other genes for diabetes (diabetes-susceptibility genes), 
metabolic environment of the body (e.g. lipotoxicity and glucotoxicity) and life-style factors 
(e.g. smoking, excess calories, stress and sedentary life style) (Hansen & Pedersen, 2005). 
The most studied of genetic differences that determine individual predisposition to T2DM are 
single nucleotide polymorphism (SNPs), which cover ~90% of the sequence variation within 
the human genome. 
 
1.9.2. Strategies in the search for the genetic basis of T2DM 
The section below briefly describes the three strategies that have been used in many studies 
to elucidate the role of polymorphisms in T2DM. 
1.9.2.1. Linkage studies 
This traditional method of identifying disease-causing genes has been used to search for 
linkage between a chromosomal region and a disease by genotyping of a large number of 
polymorphic markers in affected families (Elbers et al., 2007). 
Although linkage-based studies in affected families have shown success in providing 
consistent results on linkage but they may lack the statistical power and mapping resolution 
to identifying susceptibility alleles of complex diseases such as T2DM (Ahlqvist, Ahluwalia, 
& Groop, 2011). The Figure (1.4) below illustrates the chromosomal regions (q32, 6q22-
6q24, 11q24, 12q24, and 20q12 – 20q13) which encompasses about 612 genes which were 
found to be linked to both T2DM and obesity susceptibility (Elbers et al., 2007). 
 
1.9.2.2. Candidate gene studies 
These studies focus on the knowledge of the gene or protein function in relation to the disease 
in question to identify the relationship between certain polymorphisms and the disease-
related trait (s). Polymorphisms and association testing identified by the candidate gene 
approach can also be conducted in populations and not limited in families only as is done in 
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linkage studies. Also in these studies, a random sample of unrelated T2DM patients is 
compared with matched controls, thus identifying a polymorphic allele that occurs at a higher 
frequency in the patient group. 
 
 
Figure 1.4: Genetic linkage map for T2DM and obesity. The red bars indicate the susceptible loci for T2DM 
and the blue bars for obesity (Adopted from Elbers et al., 2007). 
 
The usual strategy of these studies concentrated on genes already known to be involved in 
insulin secretion, glucose metabolism, insulin receptors, post-receptor signaling and lipid 
metabolism. For T2DM, most candidate gene studies have focused on both genes related to 
pancreatic β-cell function (insulin secretion) and insulin action (resistance) genes (Guja, 
Gagniuc, & Ionescu-Tîrgovişte, 2012). 
 
A large number of studies have reported several functional candidate genes with T2DM, 
however association could be replicated for only 6 genes includes insulin receptor substrate  
(IRS1) and IRS-2, peroxisome proliferator-activated receptor gamma (PPARG), potassium 
inwardly-rectifying channel, subfamily J, member 11 (KCNJ11), HNF1 homeobox A 
(HNF1A), HNF1 homeobox B (HNF1B) and Wolfram syndrome 1 (wolframin) (WFS1) 
(Cheekurthy, Rambabu, & Kumar, 2016) (Kato, 2013). 
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1.9.2.3. Genome –wide association studies (GWAs) 
In contrast to candidate gene and linkage studies, genome wide association studies (GWAs) 
conducted to investigate genetic variation across the entire whole human genome regardless 
of their functionality and to identify its genetic link in the presence or absence of the disease 
(HUANG, CHENG, & Sen-Lin, 2006). Until today the GWA studies have identified nearly 
more than 70 gene loci associated with T2DM (Haddad et al., 2017) . The greater part of 
GWAs have been focused on European population. However, further studies on Asian, 
African and other populations were also done in order to improve the genetic view of the 
disease in these population  (Ng et al., 2014; Zia, Kiani, Bhatti, & John, 2013). The first 
GWA scans were published in 2007, six novel diabetes-susceptibility genes have been 
identified: SLC30A8, HHEX-IDE, CDKN2A/2B, IGF2BP2, CDKAL1 and FTO (Sladek et al., 
2007). 
 
1.9.3. Polymorphism 
About 99.9% of the human DNA sequence is the same between unrelated individuals, 
whereas only 0.1% of the coded DNA varies between two chromosomal strand (Kruglyak & 
Nickerson, 2001). DNA variation occurs in several known forms. Mutations can be defined 
as sequence variations that occur in less than 1% of the population while the more 
widespread variation are known as polymorphisms. The most common form of 
polymorphisms is the single nucleotide polymorphisms (SNPs), which are a change in a 
single base pair in the genomic DNA and may affect the gene function. Other forms of 
polymorphisms are inversions, insertions, deletions and variable number of tandem repeats 
(VNTRs). 
 
About 12 million of SNPs have been identified and genotyped by a number of genotyping 
platforms and most commonly used as marker in association studies  (I. S. M. W. Group, 
2001). About 90 % of the genetic differences among individuals is believed to be resulted 
from SNPs (Palmer & Cardon, 2005). The common form of SNPs are transition replacements 
(pyramidine-pyramidine C↔T or purine-purine A↔G) and it constitutes about 2/3 of SNPs, 
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while the other form is transversion replacements (pyramidine-purine or purine-pyramidine) 
and it constitutes about 1/3 of SNPs (Guo & Jamison, 2005). 
 
 
 
The classification of SNPs is depended on their genomic site. The coding SNPs (cSNP) are 
located in exon sequences of DNA which may be either synonymous (no change in amino 
acid previously termed “silent” but Can alter mRNA stability) or non-synonymous (changes 
amino acid conservative and radical) (Burton, Tobin, & Hopper, 2005). These SNPs have the 
potential to alter the function or availability of a protein. However, a non-synonymous SNP 
in a coding sequence can also affect the function or availability of a protein and considered as 
genetic markers for many diseases (Carlson, Eberle, Kruglyak, & Nickerson, 2004). 
 
 
1.9.4. Fat mass and obesity-associated (FTO) gene 
The epidemic nature and the prevalence of diabetes are expected to increase in Palestine. 
Since there are a little of genetic studies describing the impact of gene variants that associate 
with T2DM and related risk factors amongst Palestinians. In this study, the potential 
association of the A allele were investigated at rs9939609 of FTO gene with T2DM. To the 
best of our knowledge, this gene has not been previously tested in the Palestinian population. 
 
1.9.4.1. Mechanism of action of FTO gene 
FTO gene in human is very large gene with nine exons with more than 400 Kb on 
chromosome 16q12.2 and is well conserved in vertebrates and algae as shown in figure (1.5). 
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Figure 1.5: Schematic representation of the FTO gene chromosome 16. The obesity associated SNPs are located 
in the first intron. CUTL1 is a transcriptional activator, located in the associated region. (Adopted from(Gerken 
et al., 2007)). 
 
FTO gene is primarily expressed in the hypothalamus and encodes a 2- oxoglutarate-
dependent nucleic acid demethylase. It has homology with the AlkB family with a strong 
preference for 3-methylthymidine and 3-methyluracil in single-stranded DNA and RNA, 
respectively, owing to unique structural features (Han et al., 2012). The biochemical studies 
in vitro revealed that FTO to be a member of the Fe (II) and 2-oxoglutarate (2OG) dependent 
oxygenase superfamily  (Gerken et al., 2007).  
 
In metazoans, these enzymes are involved in a variety of processes including DNA repair, 
oxygen sensing, metabolism of fatty acid and post-translational modifications (Clifton et al., 
2006). The mechanism action of FTO gene encodes for a protein 2-oxoglutarate dependent 
nucleic acid demethylase involved in repairing DNA, post- translational modifications, 
metabolism of fatty acid, management of energy homeostasis, regulation fat masses of body 
via lipolysis and demethylation of the nucleic acid (Church et al., 2010).  
 
The FTO expression in the hypothalamus suggests a potential role in the regulation of the 
global metabolic rate, energy expenditure and energy homeostasis, regulation of body size 
and body fat accumulation and it is involved in the regulation of thermogenesis and the 
control of adipocyte differentiation into brown or white fat cells (Dina et al., 2007; 
Speakman, 2015). The full name, chromosomal location, exon number and size of the FTO 
gene is summarized in table (1.3) below. 
 
1.9.4.2. Human studies on FTO gene variants 
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Several independent studies identified a number of genetic variables in the FTO as it is 
associated with BMI and obesity. In 2007, Frayling and colleagues studied the association of 
FTO genetic variant rs9939609 and T2DM in European population the association was 
observed (OR=1.27) but once adjusted for body mass index (BMI), the association of FTO 
SNP and diabetes disappeared (OR=1.03) suggesting that this FTO variant was primarily 
affecting BMI rather than T2D risk directly (Frayling et al., 2007). Another study conducted 
at the same time by (Dina et al., 2007)  identified other genetic variants in FTO gene 
polymorphism (rs17817449, rs1421085) that were strongly associated with early-onset 
obesity among both children and adults. In addition, another study conducted by Scuteri et 
al., 2007 (GWA study) found the strong association between several variants within FTO and 
obesity (Scuteri et al., 2007). 
 
Since then, the association of FTO gene polymorphisms with obesity and BMI have been 
replicated in a number of studies and they have been expanded among Asians (Tan et al., 
2008), Europeans (Price, Li, & Zhao, 2008) as well as Africans (Adeyemo et al., 2010).  
 
Several studies also been conducted on other human measurements of obesity and show the 
FTO risk allele is associated with increased these measurements or parameters. For example, 
the FTO genetic variant rs9930506 is associated with increased waist to hip ratio (Scuteri et 
al., 2007), waist circumference, the amount of body fat (Kring et al., 2008) and fat mass 
(Andreasen et al., 2008). 
 
Few studies have investigated the FTO mRNA expression level in human adipose tissue. In 
one study, the expression level of FTO mRNA was threefold higher in subcutaneous adipose 
tissue than in visceral adipose tissue (Wåhlén, Sjölin, & Hoffstedt, 2008). Moreover, several 
studies conducted on metabolic traits related to glucose metabolism and homeostasis such as 
serum insulin, plasma glucose, insulin sensitivity and insulin resistance have shown the FTO 
genetic variant rs9939609 risk allele is associated with decreased insulin sensitivity and 
increased insulin response (Adeyemo et al., 2010). However, no significant effect was 
observed on plasma glucose levels (Müller et al., 2008), serum insulin levels or insulin 
resistance (Andreasen et al., 2008). 
 
1.9.4.3. Animal models 
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Several in vivo studies in animal models demonstrated the effect of null and loss-of-function 
mutations on expression of FTO protein, compared to in vitro experiments. The first murine 
model of global germline reduction of FTO expression was reported by Fischer et al., 2009. 
Mice with low expression of FTO suffered from a high perinatal lethality as well as postnatal 
growth characterized by reduction in body weight and length as a result of reduction in fat 
mass and resistance against diet-induced obesity as a consequence of increased energy 
expenditure. 
 
The result provided by  Fisher et al., 2009 was supported by another study conducted by 
(Church et al., 2010) showed that a dominant point mutation in the FTO gene in mice resulted 
in reduced fat mass and increased energy expenditure. Contrary to these results, a study by 
(Gao et al., 2010) showed that deletion of FTO in mice leads to increased body and fat mass. 
Food intake was significantly increased, but energy expenditure and physical activity were 
unaltered in these mice. In addition, several studies have been conducted to study the effect 
of additional copies of FTO gene and showed how these extra copies of this gene lead to a 
dose-dependent increase in fat mass as a result of increased food intake (Church et al., 2010). 
 
1.9.4.4. Gene report of FTO gene 
Table 1.3: Summary of FTO gene 
Official symbol 
 
FTO (Eynon et al., 2013) 
 
Full gene name 
 
Fat mass and obesity-associated gene (Eynon et al., 2013) 
 
Chromosomal location 
 
16q12.2 (Gerken et al., 2007) 
 
Gene ID 
 
79068 (Hubacek et al., 2012) 
 
Exon number 
 
9 exones (Gerken et al., 2007) 
 
size 
 
400,000bp (Gerken et al., 2007) 
 
Gene type 
 
Protein-coding (Hubacek et al., 2012) 
 
OMIM accession 
number 
 
610966 (Hubacek et al., 2012) 
Known as Fat mass and obesity- associated protein (Frayling et al., 2007). 
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 Alpha-ketoglutarate-dependent dioxygenase (Frayling et al., 
2007). 
Amino acid no. 
 
505 (Gerken et al., 2007) 
 
 
 
 
 
1.10 Study objectives 
In Palestine, no studies have been conducted to determine the genetic association of FTO 
variants with T2DM. Our study aimed to investigate the association of rs9939609 variant 
(T>A) in the FTO gene with T2DM among Palestinian Population. This study may provide 
valuable information for comparison with other ethnic groups. 
 
Specific objectives: 
1. To investigate the potential association of the A allele at rs9939609 of FTO gene with 
T2DM. 
2. To study the relationship between A allele at rs9939609 of FTO gene and blood pressure, 
BMI and other related metabolic parameters. 
3. To clarify the association of rs9939609 variant in the FTO gene with CVD risk in type 2 
diabetic Palestinians. 
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Chapter Two 
 
 
2. Materials and Method 
2.1. Study population 
Our study recruited 399 Palestinian participants. Among them, 281 were type2 diabetic 
patients (cases) and 118 were non-diabetic individuals (controls). Both groups were above 40 
years‟ age who attending United Nations Relief and Works Agency (UNRWA) clinics and 
residing in different regions of the West Bank (South and Middle West Bank). For diabetic 
cases, 631 patients were from Hebron, 43 from Bethlehem, 55 from Ramallah and 6 from 
Jericho. For non-diabetic participants, all of them (n=663) were from Hebron. Figure (2.6) 
indicates the sampling area. 
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                     Figure 2.6: Residency of participants admitted to the UNRWA clinics in west bank. 
 
2.2. Study design and Eligibility criteria  
A case-control study was conducted to study the association of FTO gene polymorphism 
(rs9939609) with T2DM, the Participants were unrelated, recruited within the period 2016- 
2017 based on the following criteria. 
 
 Inclusion criteria:  
Cases: 
- Males or females who were diagnosed by specialist physicians as having type 2 
diabetes based on WHO guidelines: Diabetes is diagnosed if FBG is ≥ 126 mg/dl). 
- Patients receiving treatment at UNRWA diabetes clinics and aged ≥40 years. 
Controls: 
- Males or females not diagnosed with diabetes mellitus. 
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- Residents receiving periodic follow-up at UNRWA primary health care 
clinics.  
 
 Exclusion criteria: 
- Patients diagnosed with Type 1 diabetes 
- Participants under the age of 40 years. 
- Participants with FBG ≥126 mg/dl for control subjects. 
 
 
2.3. Data collection and ethics statements 
The clinical data and medical history were recruited from the UNRWA clinic records. The 
study protocol was approved by the UNRWA officials and Al-Quds University ethics 
committee (see Appendix 1). Informed consent was obtained from all subjects before 
sampling (Appendix 2). All data was filled in a well-designed questionnaire (Appendix 3) 
containing the following data: 
 Demographic information: age, gender and place of residence. 
 Family history of diabetes mellitus in first degree relatives: father, mother, sister, brother. 
 Complications for type 2 diabetic patients: CVD, nephropathy, retinopathy and 
amputation/diabetic foot. 
 Type of medication: anti-diabetic agents (oral and insulin medication), anti-hypertensive 
and lipid lowering agents. 
 Anthropometric parameters: 
- Blood pressure: SBP (systolic blood pressure) and DBP (diastolic blood pressure). 
- Body Mass Index (BMI): person's weight in kilograms divided by height in meters 
squared (BMI=kg/m2). Subjects were considered to be normal weight if their BMI 
was < 25 kg/m
2
, overweight if their BMI was 25-29.9 kg/m
2
 and obese if their BMI > 
30 kg/m
2
. 
 Biochemical tests: 
- HbA1C: normal <5.5%.  
- Fasting blood sugar: normal (70 to 110 mg/dl). 
- Total cholesterol: normal < 200mg/dl. 
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- Triglyceride: normal <150mg/dl. 
- HDL-cholesterol: normal between 40-50 mg/dl (1.0-1.3 mmol/l) for men and between 
50-59 mg/dl (1.3-1.5 mmol/l) for women. 
- LDL- cholesterol: normal>100mg/dl (2.59 mmol/l). 
 
2.4. Data management and analysis 
All collected data was entered and arranged in excel file. For data analysis, the Statistical 
Packages for Social Science (SPSS) version 24 was used. Continuous variables (age, BMI, 
SBP, DBP, HbA1C, FBG, TC, TG, HDL and LDL) are expressed as mean ± SD. Categorical 
variables (gender, family history of diabetes, and diabetic complications) are expressed as 
percentage. The genotype frequencies were tested for Hardy–Weinberg equilibrium using a 
chi-square test through the https:// ihg.gsf.de/ihg/index_engl.html website. ANOVA was used 
to assess the association between FTO genotypes and continuous variables. Logistic 
regression by R statistics (version 2.3v) software was used to measure OR for T2DM 
adjusted for age, gender and BMI. A probability value of < 0.05 was considered significant. 
 
2.5. Methods 
2.5.1. Blood Sampling 
Whole blood samples (5 ml) were taken from all individuals by vein puncture in fasting 
status and collected in tubes containing 0.5 ml of ethylenediaminetetraacetic acid (EDTA) as 
an anticoagulant. All samples were kept at 4Cᵒ; the DNA was extracted within 24 hours. 
 
2.5.2. DNA extraction 
DNA extraction was done from all blood samples (T2DM patients and non-diabetic control) 
using NucleoSpin
®
 Tissue kit (Germany). The extraction steps were performed according to 
the manufacturer's instruction; the procedure was as followed: 
1. 25 μL Proteinase K were pipetted into the bottom of a 1.5 ml microcentrifuge tube. 
2. 200 μl samples were added to the microcentrifuge tube.   
3. 200 μl Buffer B3 were added to the sample, mixed by pulse-vortexing for 10-20 s. 
4. Mixture was incubated at 70 °C for 10–15 min. 
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5. Absolute ethanol (100%) in a volume of 210 μl was added to each sample and 
immediately mixed by vortex for 10 seconds. 
6. Mixture from step 5 was applied carefully to the NucleoSpin® Tissue Column (in a 2ml 
collection tube).  The cap was closed and column in the collection tube was centrifuged at 
11,000 x g for 1 min. Discard collection tube with flow-through and place the column in a 
new Collection Tube 
7. BW Buffer in a volume of 500 μl was added to the NucleoSpin® Tissue Column and 
centrifuged at 11,000 x g for 2 min. And discarded the filtrate. 
8. The NucleoSpin® Tissue Column was replaced in a clean 2 ml collection tube, 600 μl 
Buffer B5 were added and the tubes were centrifuged at 14,000 x g for 3 min. then 
discarded the filtrate. 
9. Finally, the NucleoSpin® Tissue Column was placed in a clean microcentrifuge tube, 100 
μl elution buffers was added to the column and centrifuged at 11000 x g for 1 min. 
10. The obtained DNA was stored at -20 ºC until further analysis. 
 
 
 
2.5.3. Genetic detection of FTO (rs9939609) polymorphism 
2.5.3.1. DNA amplification 
A fragment of 187 bp of FTO gene targeting the rs9939609 polymorphism was amplified  
using 2 primers (forward /reverse) as described previously by Adeela Shahid et al., 2013 
(Shahid et al., 2013). The primers sequences and the melting temperatures are shown in Table 
(2.4). 
 
Table 2.4: The sequence of primers used for PCR amplification of FTO (rs9939609) gene. (Shahid et al., 2013) 
 
Gene 
 
primer Sequence Tm 
(°C ) 
FTO 
rs9939609 
Forward 5‟AACTGGCTCTTGAATGAAATAGGATTCAGA3‟ 67 
Reverse 5‟AGAGTAACAGAGACTATCCAAGTGCAGTAC3‟ 69 
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2.5.3.2. PCR conditions 
A total volume of 25 μl for each PCR reaction was performed using PCR- ready mix 
(Syntezza Bioscience-Jerusalem) containing 1.2 µl of each set of primers and 5µl of the 
extracted DNA. The amplification reactions were carried out using (Gene Amp, PCR System 
9700). The PCR reaction started with initial denaturation for 5 min at 95°C followed by 35 
cycles in the following order, 30 sec. at 95°C for denaturation, 35sec at 62 °C for annealing 
and 30 sec. at 72 °C for extension, additional extension step was performed for a further 5 
min at 72 °C, assuring the complete extension of the amplified product.  The PCR product 
was frozen at -20°C until further analysis. In all amplification reactions, negative controls 
(mix without DNA) were included. 
 
2.5.3.3. Detection of PCR product 
The amplified product was visualized on 2.5 % agarose gel electrophoresis and 50bp DNA 
ladder (GeneDireX, Cat No. DM012-R500) was added to confirm the correct band size. 
 
I. Agarose gel preparation and electrophoresis 
- 2.5 grams‟ agarose (2.5%) were weighed, placed into a glass beaker, and then 100 ml of 
1X (TBE) buffer were added. 
- The agarose was boiled until it was well dissolved and clear, after that, agarose 
suspension was allowed to cool to about 40°C before it pouring. 
- Ethidium bromide (4.5 μl) was added to the solution, carefully mixed, poured into 
agarose gel casting system (Bio-Rad, SUB-CELL
®
GT) and a desired comb was inserted. 
- The comb was gently removed, and then the gel was placed in an electrophoresis chamber 
and covered (just until wells are submerged) with electrophoresis buffer (the same buffer 
that used to prepare the agarose gel). 
- At this step, the PCR product was loaded (5 μl) directly into the gel well. 3µl from 50bp 
marker (DNA ladder) was used. 
- The cathode was connected to the well side of the unit and the anode to the other side. 
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- Finally, electrophoresis was done at 120 volts, for 90 minutes (using Bio-Rad power 
supply, POWER PAC 3000) or until DNA ladder have migrated an appropriate distance, 
the movement depending on the size of the DNA to be visualized. 
 
II. Gel documentation 
In this step, agarose gel has been placed above the UV transilluminator device and then 
exposed to UV light; the photos were taken using digital camera of the gel documentation 
system (Pharmacia Biotech). 
 
2.5.3.4. Restriction Fragment Length Polymorphism (RFLP) and 
genotyping 
The A allele (rs9939609) of FTO gene was detected by RFLP, the amplified product was 
digested using ScaI restriction enzyme as previously described (Adeela Shahid et al., 2013). 
Briefly, 0.5 μl of ScaI restriction enzyme and 1.5μl restriction buffer were added to the 
amplified product for a total volume of 20 μl. The digestion reactions were incubated in water 
bath at 37°C for 1 h. The digested products were visualized on 2.5% gel as described above 
(section 2.5.3.3 I and II). Approximately, 5% of the samples was tested again to confirm the 
genotyping accuracy using the same method. 
2.5.4. Sequence analysis 
To validate the genotyping results, 5% of samples were randomly selected but representing 
the three genotypes and sent for sequencing. The PCR product was purified and sequenced in 
both directions by HyLab sequencing service (Rehovot, Israel). The obtained sequences were 
assembled using Bioedit software, used in a BLAST search (ncbi.nlm.nih.gov/blast) and 
aligned with each other. 
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Chapter Three 
 
3. Results 
3.1 . Study Subjects 
A total of 399 participants were recruited in this study (281 with T2DM and 118 non-diabetic 
individuals). The male to female ratio was 94:187 in diabetic group compared to 48:70 in 
control as shown in table (3.5). There was no significant difference in gender of T2DM 
patients compared to those of non-diabetic control group (P=0.164), while a significant 
difference in the mean age among the two groups was observed (P = 0.0001). 
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Table 3.5: Number of study subjects. 
 
Variable 
Type 2 
diabetic 
Patients 
n=281(%) 
 
Non-diabetic 
Controls 
n=118(%) 
 
P-value 
Gender   
Male
 
94 (33.5%) 48 (40.7%) 0.164 
Female
 
187 (66.6%) 70 (59.3%) 
Total 281 (100%) 118 (100%)  
Age 
(means ±SD ) 
58.15±12.09 49.62±8.71   0.0001 
Age at diagnosis 
(means ±SD ) 
50.39±11.05 N.A  
P<0.05 is considered to be significant, N.A; Not Available 
 
 
 
 
 
 
3.2 . Clinical and biochemical characteristics of the study subjects 
The clinical and biochemical characteristics were compared between type 2 diabetic and non-
diabetic groups.  The results indicate that there are significant differences in all clinical and 
biochemical parameters except of TC (P = 0.251) among the two groups as shown in table 
(3.6).  
 
Table 3.6: comparison of the Clinical and biochemical characteristics in diabetic and non-diabetic groups. 
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Clinical 
characteristics 
 
Type 2diabetic  
patients 
n=281 
 
Non-diabetic  
controls 
n=118 
 
 
 
P-value 
SBP (mmHg) 136.21(±17.42) 122.33(±11.44) 0.0001
 
DBP (mmHg) 80.21(±10.83) 76.72(±9.37) 0.0024
 
FBS (mg/dl) 163.31(±58.72) 87.14(±7.82) 0.0001
 
HbA1c (%) 8.03(±2.01) N.A  
TG (mg/dl) 181.25(±123.23) N.A  
TC (mmol/l) 187.91(±47.53) 182.15(±40.95) 0.251
 
HDL (mg/dl) 42.09(±10.66) N.A  
LDL (mg/dl) 108.86(±26.71) N.A  
Values are expressed as means ±SD, P<0.05 is considered to be significant, N.A; Not Available 
 
 
3.3 . Body mass index 
Body mass index (BMI) values were calculated in the group of T2DM patients and non-
diabetic control group according to the following equation:  
                           BMI = (weight in kg) / (height in meters) 
2 
Participants were classified according to World Health Organization (WHO) classification of 
obesity (BMI Classification, 2012). The results indicate that there are significant differences 
in the mean BMI among T2DM patients and non-diabetic control group (32.9±6.6 vs. 29.2 
±6.2; P<0.0001) respectively). Furthermore, the frequency of obesity (BMI of 30 or greater) 
was significantly higher among T2DM patients than non-diabetic controls (64.4% vs. 44.1%; 
P=0.0002) as shown in table (3.7). 
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Table 3.7: BMI distribution of the study subjects. 
Values are expressed as frequencies (%), P<0.05 is considered to be significant. 
 
 
 
3.4.  Microvascular and Macrovascular complications in type 2 diabetic 
patients 
Our results showed that 41% (114/281) of type 2 diabetic patients suffer from at least one of 
the following complications; retinopathy, nephropathy, diabetic foot and CVD. Our study 
revealed that the most prevalent complication was CVD (14.6%) followed by nephropathy 
(12.1%), diabetic foot (7.8%) and retinopathy (6%) as shown in table (3.8).  
 
 
Table 3.8: prevalence of microvascular and macrovascular complications among type 2 diabetic patients. 
 
 
          complications 
 
No. of type 2 diabetic patients (%) 
 
 
 
 
Type 2 diabetic 
patients 
n (%) 
 
Non-diabetic 
control 
n (%) 
 
 
P-value 
BMI(kg/m
2
) 
(means ±SD )
 32.9 ± 6.6 29.2 ± 6.2 <0.0001 
Normal 
(18.5-24.9 kg/m
2
)  
15 (5.3%) 39 (33.1%)  
<0.0001 
Over weight 
(25-29.9 kg/m
2
) 
85 (30.2%) 27 (22.9%) 
0.23 
Obese 
( ≥ 30 kg/m2 ) 
181 (64.4%) 52 (44.1%) 
0.0002 
Total 281 (100%) 118 (100%)  
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    Microvascular complications 
Retinopathy 17(6%) 
Nephropathy 34(12.1%) 
Diabetic Foot 22(7.8%) 
   Macrovascular complication 
CVD 41(14.6%) 
Total 114 
 
 
Our results revealed that (74.7%) of diabetic patients have first degree family history of 
diabetes.  T2DM complications were compared among patients with and without family 
history of diabetes as shown in table (3.9). Our results showed that the prevalence of 
retinopathy was significantly higher among patients without family history of diabetes 
compared to those with family history of diabetes (P= 0.001). However, no significant 
difference was seen between and T2D complications (P <0.05). 
 
Table 3.9: Frequencies of diabetic complications among type 2 diabetic patients with and without first degree 
family history of diabetes. 
 
 
 
Complications 
Type 2 Diabetic Patients  
 
P-value 
Family History 
n=210 
No Family 
History 
n=71 
Retinopathy 7(3.3%) 10(14.08%) 0.001
 
Nephropathy 27(12.85%) 7(9.85%) 0.503 
Diabetic Foot 15(7.14%) 7(9.85%) 0.461 
CVD 41(14.76%) 10(14.08%) 0.889 
Values are expressed as frequencies (%), P<0.05 is considered to be significant. 
3.5. Anti-diabetic treatment at the time of sampling 
The current study revealed that 6 (2.13%) of T2DM patients were treated with insulin, 204 
(76.59%) were treated with oral hypoglycemic agents while 71 (25.26%) received a 
combination of insulin and oral hypoglycemic agent. The results were shown in Figure (3.7). 
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Figure 3.7: Percentages of type 2 diabetes route of treatment. 
 
3.6. Genotyping 
3.6.1. Measurement of DNA concentration and purity 
DNA quantity and purity was estimated by measuring the concentration in ng/ul and 
A260/A280 ratio. The concentration was ranged from 50-200 ng/ul. The results of 
representative samples are shown in the table (3.10). 
260/230 Ratios 
Few contaminants have characteristic profiles, e.g. phenol, however many contaminants have 
similar characteristics. Absorbance at 230 nm or less. Abnormality 260/230 values may 
indicate there was a problem in the sample or in the extraction protocol, therefore it is 
important to consider both 
260/280 Ratios 
The abnormal 260/280 ratios frequently indicate that the sample was either contaminated by 
protein or with a reagent such as phenol or that there was an issue with the measurement. 
Table 3.10: Results of DNA concentration and purity 
DNA sample ng/ul A260 A280 260/280 260/230 
1 105.49 2.11 1.17 1.8 1.34 
2 117.4 2.349 1.225 1.92 1.52 
3 70.77 1.415 0.759 1.87 1.39 
 
76.59% 
2.13% 
25.26% 
Diabetes Medications 
Oral Insulin Oral/Insulin
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3.6.2. DNA amplification 
The amplification product of FTO gene polymorphism (rs9939609) was evident to have a 
size of 187 bp amplicon as described by Adeela Shahid et al., 2013. Sizes of amplicons were 
confirmed by agarose gel electrophoresis as shown in figure (3.8).  
 
 
Figure 3.8: PCR product of FTO gene polymorphism (rs9939609) analyzed by agarose gel electrophoresis. 
DNA was extracted from blood; amplification was carried out for the FTO gene (rs9939609) using specific 
primers and template DNA. The PCR product was electrophoresed on 2.5% agarose (120V and 90 min.) and 
directly visualized with ethidium bromide under UV light.  
Line 15: DNA markers (Ladder 50 bp) N.C: Negative control Line 1-14: PCR product, ampilcon size 187bp 
 
 
3.6.3. RFLP analysis 
To determine the genotype of the studied population, the PCR product of FTO gene 
polymorphism (rs9939609) was digested by ScaI restriction enzyme and visualized by 
agarose gel electrophoresis as described previously (Adeela Shahid et al., 2013). A band of 
(187 bp) was observed on 2.5% agarose gel for the wild type genotype (TT), two bands of 
(154, 33 bp) was observed for the homozygous recessive genotype (AA) while three bands of 
(187, 154, 33 bp) were observed for the heterozygous genotype (TA) and as shown in table 
(3.11) and figure (3.9). 
Table 3.11: Number and size of bands that observed on 2.5% agarose gel for each genotype. 
Genotype No. of bands Size of bands (bp) 
Wild type TT 1 187 
Heterozygous TA 3 187, 154, 33 
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Figure 3.9: Results of FTO gene polymorphism (rs9939609) product on agarose gel electrophoresis. PCR 
product of FTO gene (rs9939609) was digested with ScaI restriction enzyme. The products of digestion were 
electrophoresed on 2.5% agarose (120V and 90 min) and directly visualized with ethidium bromide under UV 
light.  Line 15: DNA Marker (Ladder 50 bp) 
Line: 2, 3, 6, 7 and 13: TT genotype 187 bp 
Line: 1, 4, 5, 9, 10 and 12: TA genotype 187, 154, 44 bp. 
Line: 8, 11, and 14: AA genotype 154, 44 bp 
 
 
3.6.4. Sequencing of FTO gene polymorphism (rs9939609) 
The PCR product was purified and sequenced in both directions (forward /reverse). Examples 
on the sequencing results for the three different genotype are illustrated in figure (3.10 A, B 
and C). 
 
 
Homozygous AA 2 154, 33 
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Figure 3.10: DNA sequencing results of FTO (rs9939609) variant in three different genotype. A) TT genotype 
of rs9939609 SNP T<A. B) AA genotype of rs9939609 SNP T<A. C) AT genotype of rs9939609 SNP T<A. 
 
 
 
3.6.5. Genotype and allele frequencies 
The genotype and allele frequencies of FTO gene polymorphism (rs9939609) in type 2 
diabetic patients and non-diabetic control were analyzed and shown in table (3.12). The 
results indicated the frequency of homozygous genotype (AA) allele was significantly higher 
in T2DM patients when compared with those of non-diabetic control (36% vs. 16%). The 
minor allele frequency (A allele) was 58.8% in T2DM patients and 38.9% in non-diabetic 
controls. The genotyping distribution was in Hardy Weinberg equilibrium in both the control 
(P=0.679) and diabetic groups (P=0.384).  
 
 
A B 
C 
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Table 3.12:  genotypic and allelic frequency of FTO gene polymorphism (rs9939609) in type 2 diabetic patients 
and non-diabetic control. 
 
 
Genotype 
 
Type 2 diabetic patients 
n=281 
 
Non-diabetic control 
n=118 
TT 51 45 
TA 129 54 
AA 101 19 
MAF (%) 58.8% 38.9% 
 
 
3.6.6. Association of FTO gene polymorphism (rs9939609) with response to 
type 2 diabetes mellitus 
The association of FTO genotyping with type 2 diabetic was examined by logistic regression 
analysis with the use of co-dominant and recessive models as shown in table (3.13). Strong 
association was found between the minor A allele (rs9939609) of the FTO and increased 
T2DM risk with an allelic odd ratio (OR) of 2.11 (95% CI [1.26-3.52], unadjusted P 
<0.0001); this association was partly attenuated after adjustment by age, gender and BMI 
with an allelic odd ratio (OR) of 1.84 (95% CI [1.04-3.05], P=0.034 as shown in table (3.13).  
 
Table 3.13: Association of FTO gene polymorphism (rs9939609) with type 2 diabetes mellitus. 
 
 
Genotype 
 
 
OR (95% CI) 
 
 
P-value 
 
 
OR (95% CI) 
 
*
P-value 
AA vs TT 4.69 (2.49–8.83) <0.0001 4.03 (2.01–8.06) <0.0001 
TA vs TT 2.11 (1.26-3.52) <0.0001 1.84 (1.04-3.05) 0.034 
AA vs (TA+TT) 2.78 (1.72-4.49) <0.0001 2.71 (1.5-4.9) 0.001 
P<0.05 is considered to be significant, 
*
P- value adjusted by age, gender and BMI. 
 
 
 
   40 
 
3.6.7. Clinical characteristics of study subjects according to FTO gene             
polymorphism (rs9939609) genotype 
The clinical and biochemical parameters (BMI, SBP, DBP, FBS, and TC) of study subject‟s 
relative to the FTO gene polymorphism (rs9939609) were analyzed by using ANOVA test as 
shown in table (3.14). Our results demonstrated a weak but not significant association 
between FTO (rs9939609) genotype and BMI in the group of type 2 diabetic patients 
(P=0.057), while no association was found in the group of non-diabetic control (P=0.688). 
Moreover, no significant association was seen in the other investigated parameters (SBP, 
DBP, FBS, and TC) across FTO (rs9939609) genotype (P <0.05) as seen in table (3.14). In 
addition, no association was observed between the levels of glycated hemoglobin (HBA1C) 
and FTO genotypes: AA (7.845 ± 1.88), TA (8.02 ± 2.03) and TT (8.43 ± 2.17). 
 
Table 3.14: clinical characteristics of study subjects according to the FTO (rs9939609) genotype. 
                                   
          
Type 2 diabetic patients 
      n=281 
 
 
Non-diabetic controls 
n=118 
 
 TT       
(n=51) 
TA 
(n=129) 
AA 
(n=101) 
   P-
value 
TT   
(n=45) 
TA 
(n=54) 
AA 
(n=19) 
   P-
value 
Age 57.8±12.3 58.4±11.9 58.1±12.3 0.952 48.6±8.9 50.9±8.6 48.3±8.2 0.329 
BMI 
(kg/m
2
) 
31.8±6.5 32.3±6.1 34.1±7.1 0.057 28.75±5.8 29.77±6.1 28.89±6.96 0.688 
SBP 
(mmHg) 
135.4±20.4 138.2±16.4 133.9±16.9 0.166 121.4±9.5 124.2±10.7 119.3±16.3 0.222 
DBP 
(mmHg) 
81.3±10.5 80.9±10.1 78.6±11.9 0.206 78.5±8.1 76.7±10.2 72.8±9.2 0.087 
FBS 
(mg/dl) 
169.9±65.6 163.9±58.9 159.1±54.3 0.553 86.9±8.8 87.7±7.4 85.9±6.9 0.693 
TC 
(mg/dl) 
183.7±39.8 188.5±49.2 189.1±49.3 0.783 180.4±28.2 188.5±48.8 168.1±40.1 0.165 
P<0.05 is considered to be significant. 
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3.6.8. Association of FTO (rs9939609) gene polymorphism with 
macrovascular and microvascular complications in T2DM patients 
 
The association of the FTO (rs9939609) genotype and T2DM complications (Retinopathy, 
Nephropathy, Diabetic Foot and CVD) of study participants were studied. Our results 
demonstrated insignificant association (P>0.05) of various complications with FTO 
(rs9939609) genotype as shown in table (3.15).   
 
 
 
Table 3.15: Type 2 diabetes complications according to FTO (rs9939609) genotype. 
                                                           
 
 
 
Complications 
 
No. of T2DM complications across 
FTO genotypes 
 
       
 
P-value 
TT 
 n (%) 
TA 
         n (%) 
AA 
 n (%) 
Microvascular 
complications 
 
Retinopathy 5 (9.8%) 6 (4.6%) 6 (5.9%) 0.425 
Nephropathy 6 (11.7%) 17 (13.2%) 11(10.9%) 0.867 
Diabetic Foot 3 (5.8%) 14 (10.8%) 5 (4.9%) 0.216 
Macrovascular 
complication 
 
CVD 5 (9.8%) 18 (13.9%) 18 (17.8%) 0.401 
Total 19 (37.1%) 55 (42.5) 40 (39.5%)  
P<0.05 is considered to be significant 
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Chapter Four 
 
4.1. Discussion 
Type 2 diabetes mellitus is a common metabolic disorder characterized by hyperglycemia 
with disturbances in fat, carbohydrate and protein metabolism. The two major 
pathophysiological defects in T2DM are impaired insulin secretion, insulin action, or both. 
These metabolic abnormalities lead to long term damage of different organs, causing their 
dysfunction and failure. Type 2 diabetes related microvascular complications are responsible 
for the majority of new cases of kidney failure, blindness and diabetic foot amputation. 
Furthermore, macrovascular complications such as CVD and stroke related deaths are 2-4 
times more frequent in adults with diabetes than in the general population. 
The number of confirmed loci involved in the development of T2DM has increased from 3 in 
2006 to over 70 to date. Taking into consideration the impact of genetics and environmental 
factors such as diet and physical activity on developing this disease (Maggie et al., 2014). 
The differences in susceptibility of different ethnic groups may be explained. Most of these 
variants have modest effects on disease risk (with an odds ratio ~ 1.2) and their role in the 
development of T2DM is still poorly understood. However, the association of FTO variants 
with T2DM in the MENA (Middle East and North Africa) region is not well studied. In the 
present case-control study, we investigated the potential association of the minor A allele at 
rs9939609 of FTO gene with T2DM and its related complications among Palestinian 
population.  
Microvascular (retinopathy, nephropathy and diabetic foot), and macrovascular (CVD) 
complications are common among people with T2DM and have profound effects on patient‟s 
morbidity and mortality. In this study, we noted that 74.7% of T2DM patients had first 
relative family history to diabetes and 41% developed T2DM complications. The prevalence 
of retinopathy was significantly higher among patients without family history to diabetes this 
could be attributed to several factors -other than family history- that widely recognized as 
major risk factors for the development of diabetic retinopathy including severity of 
hyperglycemia, present of hypertension and diabetes duration (Antonetti et al., 2012). CVD 
was the most prevalent (14.6%) compared to other complications which is in line of several 
studies reported  that diabetes is recognized to be an independent risk factor for CVD (Palem, 
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2017; M. K. Poulsen et al., 2010) As expected, the levels of biochemical parameters that refer 
to T2DM risk factors were significantly higher in participants with T2DM compared to the 
healthy control group confirming that T2DM is associated with hypertension, hyperglycemia 
and other abnormal metabolism dysfunctions.  
The association between obesity and T2DM has long been established and recognized across 
all ethnic groups. In this investigation, we found that 86.4 % of all participants were 
overweight and obese compared. These results reflect the increase of obesity in the 
Palestinian population as a result of lifestyle turns toward physical inactivity, urbanization 
and increased fast food consumption. Thus, there is a need to educate people with increased 
risk of metabolic diseases that associated with obesity and its related traits. In morbid obesity, 
the expression rate of various insulin signaling molecules is reduced and several mechanisms 
such as docking translocation and fusion of Glucose transporter-4 (GLUT-4) containing 
vesicles with the plasma membrane are impaired leading to insulin resistance, a major risk 
factor for T2DM (Goodyear et al., 1995; Kahn et al., 1992). Insulin resistance is a risk factor 
of T2DM and many other metabolic traits. However, it has been shown that not all 
individuals with insulin resistance should develop T2DM, only about 20% of obese 
individuals develop the disease while most are able to maintain blood sugar level (Lan et al., 
2003). Aging has also been identified as an important risk factor for many metabolic 
disorders including T2DM (Kautzky-Willer et al., 2016). In the current study, we observed a 
significant difference in age between T2DM patients (58.15±12.09) and control groups 
(49.62±8.71), P <0.0001, indicating that age was one of the factors contributing to the high 
prevalence of T2DM noted in our population. 
 
In this study, we evaluated the effect of FTO (rs9939609) variant on predisposition of T2DM 
in the Palestinian population. Statistically significant association was found between the 
minor allele A of the FTO gene and increased risk of T2DM with an allelic OR of 1.84 after 
adjustment for age, gender and BMI. The association with FTO rs9939609 variants with 
T2DM was first described by Frayling et al, 2007.  Afterwards, similar findings were 
reported in different populations including Europeans (Freathy et al., 2008) and South Asian 
Indians (Yajnik et al., 2009). 
 
   44 
 
In this study, the minor allele frequency (MAF) was 58.8% in diabetic group which is higher 
than A allele frequency in South Asian population (35%) (Rees et al., 2011), Chinese 
(12%)(Li et al., 2008), Japanese (18%) (Omori et al., 2007) , Europeans (45%) (Freathy et al., 
2008), South Asian Indians (30%) (Yajnik et al., 2009) and Egyptian (39%) (Khella, Hamdy, 
Amin, & El-Mesallamy, 2017) indicating that genetic makeup may play a critical role in 
leading of T2DM in Palestinian population. 
 
On the other hand, several studies have demonstrated that the association of FTO 
polymorphisms with T2DM is mediated by obesity (Cauchi et al., 2008; Thorleifsson et al., 
2009). However, our results showed no association with FTO (rs9939609) gene and BMI in 
diabetic patients and control group (P= 0.057 and P=0.688, respectively) indicating that FTO-
T2DM association was not mediated by BMI and the high prevalence of obesity in our 
studied population may be attributed to other FTO variants / other genes and environmental 
factors. In addition, our results were inconsistent with a study by Chang et al. showed that the 
minor A allele at rs9939609 of FTO gene was strongly associated with obesity and BMI in 
the Chinese population. Also, a study conducted by (Dina et al., 2007) identified SNPs in 
FTO gene that which were strongly associated with early-onset obesity among both children 
and adults in European population. In contrast, another study found a borderline evidence that 
FTO genotypes are associated with BMI in Asians population (Ng et al., 2008). ). 
Furthermore, several studies showed no association of FTO variants and BMI (Jacobsson et 
al., 2009). The inconsistency of the reported studies revealed the differences in the genetic 
background, diets and lifestyle. Several studies reported about the effect of physical activity 
and diet on FTO variants, some of these studies have been clarified that its obesity-increasing 
effect may be suppressed in individuals who are physically active (Ahmad et al., 2011). 
While, other studies have not replicated this interaction, leaving it unresolved whether 
physical activity can reduce FTO impact on the risk of obesity (Jonsson et al., 2009). 
 
Moreover, we investigated the association of FTO variant with T2DM related complications, 
no significant difference between T2DM complications across FTO genotypes, P<0.05 was 
observed. These results are in contrast to several studies which reported an association of 
FTO variants with T2DM complications. A study conducted by Hubacek et al., 2012 
described the association of variants in this gene with end-stage renal disease (Hubacek et al., 
2012).  Another study conducted by (Doney et al., 2009) described that AA genotype of the 
FTO rs9939609 variant was associated with increased CVD risk in men with either impaired 
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glucose tolerance or type 2 diabetes and the association was not explained by the 
conventional CVD risk factors. 
  
 
4.2. Conclusions 
This study is the first in Palestine that investigated the effect of FTO (rs9939609) variant on 
T2DM and BMI. Our results showed strong association between FTO (rs9939609) variant 
and T2DM but not BMI.  Moreover, no significant association was observed between this 
variant and age, gender, T2DM complications or other biochemical parameters.   
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4.3 . Recommendations 
1. In diabetic clinics in UNRWA, BMI was used only for reference obesity. Other important 
measures such as WC, WHR should be added which can be of great importance for future 
studies. 
2. Analysis of more SNPs of FTO genes to determine which one is more common in our 
population. 
3. Evaluation of gene expression to determine the effect of SNPs on the various phenotypic 
parameters. 
4. Further large-scale study is required to elucidate the role of other FTO variants/other gene 
and environmental factors on the high prevalence of obesity in Palestinian population.   
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 ػٕٛاْ اٌجحث:  
 2 epyT ni snoitacilpmoC ralucsavorcaM htiw tnairaV 9069399sr OTF fo noitaicossA"
 "noitalupoP nainitselaP gnoma sutilleM setebaiD
  اثٛ د٠ظ -جبِؼخ اٌمذط اٌجحث:ِىبْ إجشاء 
اٌشجبء أْ رأخز(ٞ) اٌٛلذ اٌىبفٟ ٌمشاءح   اٌمذط.أٔذ ِذػٛ(ح) ٌٍّشبسوخ ثجحث ػٍّٟ عش٠شٞ ع١جشٜ جبِؼخ 
اٌّؼٍِٛبد اٌزبٌ١خ ثزأْ لجً أْ رمشس(ٞ) إرا وٕذ رش٠ذ(٠ٓ) اٌّشبسوخ أَ لا.  ثئِىبٔه طٍت إ٠ضبحبد أٚ ِؼٍِٛبد إضبف١خ 
 أٚ ػٓ ٘زٖ اٌذساعخ. الاعزّبسحػٓ أٞ شٟء ِزوٛس فٟ ٘زٖ 
ٚاٌّخبطش إٌبجّخ ػٓ  اٌثبٟٔ،ٞ ِٓ إٌٛع ٌّشض اٌغىشع١زٕبٚي ٘زا اٌجحث اٌخصبئص اٌج١ٕ١خ ٚاٌٛساث١خ  . أ
ع١زُ اٌجحث ثبٌّغججبد اٌٛساث١خ ٚاٌزشٛ٘بد اٌج١ٕ١خ  اٌذِٛ٠خ ثح١ث٘زا اٌّشض وأِشاض اٌمٍت ٚالاٚػ١خ 
 ٚالاِشاض.اٌزٟ ٠ّىٓ اْ رىْٛ ػبِلا سئ١غ١ب فٟ اٌزغجت ثّثً ٘زٖ اٌّخبطش 
 
أٞ ِٓ اٌّخبطش أٚ ا٢ثبس اٌجبٔج١خ اٌزٟ ٠ّىٓ  دَ دْٚ٠طٍت ِٕه رمذ٠ُ ػ١ٕخ  ٘زٖ،ِغ اعزّبسح اٌّٛافمخ  . ة
اٌطج١خ ربس٠خه  ػٍٝ عجلاره اٌذساعخ الاطلاعوّب رزضّٓ  اٌذساعخ.حذٚثٙب ِٓ جشاء ِشبسوزه/ٞ فٟ ٘زٖ 
 اٌطجٟ.
  
اٌمٍت ٚالاٚػ١خ  لأِشاضاخٟ اٌّٛاطٓ اشزشاوه فٟ ٘زا اٌجحث لذ ٠غُٙ فٟ ػٍّ١خ اٌزشخ١ص اٌّجىش  . د
 اٌّشض.ِٓ ٘زا  ٚالشثبئىُ ثبٌّغزمجًع١غبػذ فٟ اٌٛلب٠خ ٚاٌؼلاج ٚوزٌه ٌ١مٟ اثٕبءوُ  اٌذِٛ٠خ ٚثبٌزبٌٟ
 
طٟ  اعّهفٟ حبي ٚافمذ ػٍٝ اٌّشبسوخ فٟ ٘زٖ اٌذساعخ، ع١جمٝ ٘زٖ اٌذساعخ ِغأٌخ رطٛػ١خ رّبِب، ٚ فٟاْ ِشبسوزه 
ػٍٝ ٍِفه اٌطجٟ ثبعزثٕبء  الاطلاعٌٓ ٠ىْٛ لأٞ شخص، ِب ٌُ ٠ٕص اٌمبْٔٛ ػٍٝ رٌه، حك   ربِخ.ٚثغش٠خ اٌىزّبْ 
  اٌحىِٛ١خ إٌّظّخ.  الإداساد ِٚفزش١ٓ ِٓاٌطج١ت اٌّغؤٚي ػٓ اٌذساعخ ِٚؼبٚٔ١ٗ، ٌٚجبْ الأخلاق إٌّٙ١خ اٌّغزمٍخ، 
  
 
 :ِٛافمخ اٌّشزشن
ِخزبسا، ، حشا ٚثٕبء ػٍ١ٗ فإٟٔٔ ػٍٝ أعئٍزٟ جّ١ؼٙب.  الإجبثخٌمذ لشأد اعزّبسح اٌمجٛي ٘زٖ ٚفّٙذ ِضّٛٔٙب. رّذ 
ػٍُ اْ اٌجبحث أٔظ سصق صجبسٔٗ ٚصِلاءٖ ع١ىْٛٔٛ ِغزؼذ٠ٓ أٟ إٔٚ ،شزشان ف١ٗالإ ػٍٝأٚافك ٚجشاء ٘زا اٌجحث إج١ض أ
 .ئٍزٟعأجبثخ ػٍٝ ٌلإ
                        ------------------------------            --------------------------------------------
 رٛل١غ اٌّشزشن        اٌّشزشن اعُ
 ------------------------ ٌزبس٠خا
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Appendix 3 
Questionnaire 
 
 
 طذمٌا خؼِبج 
 
   تطٌا خ١ٍو 
 
   ظٌدىبأ– طذقىا  
     
Al-Quds University  
 
Faculty of Medicine  
 
Abu-Dies, Jerusalem  
 
Case     Control     Q. No.:  
 
            
Have you ever suffered from?   
Hypertension                  Diabetes Mellitus (T2D)                Cardiovascular disease   
                                                            
Sys/Dias blood pressure (SBP/DBP) ---------------- 
 
Family history for D.M/ 1st relative degree:     
 
Name----------------------------                        
Age------------------------------                        Gender-------------------------------- 
Religion ------------------------ Geographic area ------------------ 
Weight (kg)-------------------------- 
Length (cm)-----------                
BMI-------------    WHR------------- 
Physician‟s name: --------------------               Address-------------     Tel. -------------- 
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          Yes                  No                
For diabetic patients only:  
Age of onset/at diagnosis -------------- (yrs.)  
Weight at diagnosis ----------------- (kg) 
 
Complications:  
Coronary heart disease               Nephropathy                           Retinopathy   
 
Medication:        
Anti-diabetic agents                           Anti-hypertensive            Lipid lowering agents 
----------------------- 
------------------------ 
    
Biochemical Tests: 
FBS mg/dl 
HbA1C                   % 
Total cholesterol mg/dl 
Triglycerides mg/dl 
HDL-c mg/dl 
LDL-c mg/dl 
VLDL-c  
LDL/HDL  
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 ralucsavorcaMِغ ِضبػفبد الاٚػ١خ اٌذِٛ٠خ  )9069399sr( OTFاٌؼلالخ ث١ٓ اٌّزغ١ش اٌج١ٕٟ 
 ٓاٌفٍغط١ٕ١١ث١ٓ اٌغىبْ    sutillem setebaid 2 epyTفٟ إٌٛع اٌثبٟٔ ِٓ ِشض اٌغىشٞ  snoitacilpmoC
 
  أٔظ سصق حغٓ صجبسٔٗ ػذاد:إ
  د. عٙ١ش ػش٠مبد إششاف:
 
 اٌٍّخص
 عن سكر الدم الناجم بارتفاعمجموعة من الأمراض الاٌضٌة التً تتمٌز  هى )MD2T(مرض السكري من النوع الثانً
العلمٌة فً السنوات الاخٌرة أن هناك علاقة  الأبحاثأظهرت  كلاهما.أو  الأنسولٌن،أو عمل  الأنسولٌن،خلل فً إفراز 
بٌن الوراثة وهذا النوع من السكري أٌضا المضاعفات الناجمة عن المرض والتً تشمل كل من اعتلال الشبكٌة 
) واٌضا امراض القلب toof citebaiDأضرار القدم ( )،yhtaporhpeNالكلى ( اعتلال ،)yhtaponiteR(
وجد انها مرتبطة ارتباطا  حٌث )OTFجٌن ال ( فً )stnairaVتم تحلٌل العدٌد من المتغٌرات (  الدموٌة.والأوعٌة 
) التً تعتبر عاملا من العوامل التً فرص الاصابة بهذا المرض فً ytisebOقوٌة مع هذا النوع من السكري والسمنة (
ٍغ ٍشض  )9069399sr( OTFجٌنً لذلك صممت هذه الدراسة لتشخٌص العلاقة بٌن التباٌن ال السكان.مختلف 
 اىَشض.واىَضاػفاث اىْاجَت ػِ هزا  )،MD2T(اىغنشي ٍِ اىْىع اىثاًّ 
ً ػيى ٍجَىػخٍِ الأوىى حشَو ٍشض اىغنشي ٍِ  2616-1616 اجرٌت هذه الدراسة خلال الفترة الزمنٌة الممتدة من
ٌؼاّىُ ٍِ اىغَْت  لا 12وٍشٌضا ماّىا ٌؼاّىُ ٍِ اىغَْت اىَفشطت  282(ٍشٌضا  281وػذدهٌ ) MD2T(اىْىع اىثاًّ 
شخصا  11( 822ٍِ أي ٍشامو صذٍت وػذدهٌ  اٌؼاّىأٍا اىَجَىػت اىثاٍّت شَيج ػيى اشخاص عيٍٍَِ ولا  اىَفشطت)،
جٍَغ اىَشاسمٍِ فً هزٓ اىذساعت ٍِ ملا  اىغَْت).لا ٌؼاّىُ ٍِ  شخصا 39وماّىا ٌؼاّىُ ٍِ اىغَْت اىَفشطت 
حٌ جَغ اىبٍاّاث اىَخؼيقت  ػاٍا.وحخشاوح أػَاسهٌ فىق عِ الأسبؼٍِ  )،detalernu(اىَجَىػخٍِ لا حجَؼهٌ صيت اىقشابت 
حٌ حذذٌذ   اىذٍىٌت.ٍْظٌ اشخَو ػيى مافت اىبٍاّاث اىغشٌشة واىنٍٍَائٍت  اعخبٍاُاىذساعت ٍِ خلاه  هزٓباىَشاسمٍِ فً 
. حٌ اعخخذاً اىخذاىٍو الإدصائٍت اىىصفٍت PLFR-RCP(ٍخبىػا بخقٍْت (  RCPجٍِ ٍِ خلاه  )OTF(اىَخغٍش اىجًٍْ ه 
اٌضا اعخخذاً  اىذساعت،) ىيَقاسّت بٍِ ٍجَىػخً tset erauqs-ihC s‟nosraePىخقٌٍ اىَؼطٍاث واىخً شَيج مو ٍِ (
   ).erawtfos .)0.8.2v( scitsitats R(
ٍغ صٌادة  )9069399sr( OTFاىجًٍْ  ىيَخغٍش )A( ىلأٌوأظهشث ّخائجْا اىخً حىصيْا اىٍها اىى وجىد اسحباط قىي  
 بعد )430.0=P ،]50.3-40.1[ IC%59( ,48.1=RO( )MD2T(خطش الاصابت بَشض اىغنشي ٍِ اىْىع اىثاًّ 
 ىيَخغٍش )A( ىلأٌوأٌضا لوحظ ان هناك ارتباطا ضعٌفا  .)IMBالجسم ( ومؤشر كتلةالتعدٌل بالنسبة للعمر والجنس 
 P(الثانً ) لدى مجموعة المصابٌن بمرض السكر من النوع IMB(ٍغ ٍؤشش مخيت اىجغٌ  )9069399sr( OTFاىجًٍْ 
 ٌلادع وجىد أيأٌضا ىٌ  .)886.0 = P(فً دٍِ ىٌ ٌخٌ اىؼثىس ػيى هزا الاسحباط فً اىَجَىػت اىثاٍّت  ،)750.0 =
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واىَضاػفاث اىْاجَت ػِ هزا اىَشض  اىؼَش واىجْظٍِ  ومو )9069399sr( OTFاسحباط بٍِ اىَخغٍش اىجًٍْ 
 .)50.0>P(
وصٌادة خطش الاصابت  )9069399sr( OTFاىَخغٍش اىجًٍْ  قىٌا بٍِأظهشث ّخائجْا اُ هْاك اسحباطا  اىخخاً،فً 
هْاك داجت قىٌت اىى ٍضٌذ ٍِ اىذساعاث واعؼت اىْطاق ىخىضٍخ  رىل،ٍغ  .)MD2T(بَشض اىغنشي ٍِ اىْىع اىثاًّ 
 الفلسطٌنٌٌن.) لدى السكان IMBاىجغٌ (اٌضا فً صٌادة ٍؤشش مخيت  )9069399sr( OTFدوس هزا اىَخغٍش 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
